Department of Biomedical Engineering, New Jersey Institute of Technology, 138 Warren St. LSEB 316, Newark, NJ, 07102, USA.
Casey Eye Institute, Oregon Health & Science University, Portland, OR, 97239, USA.
Drug Deliv Transl Res. 2020 Oct;10(5):1191-1202. doi: 10.1007/s13346-020-00753-0.
The retinal physiology can accrue oxidative damage and inflammatory insults due to age and metabolic irregularities. Two notable diseases that involve retinal and choroidal neovascularization are proliferative diabetic retinopathy and wet age-related macular degeneration. Currently, these diseases are mainly treated with anti-VEGF drugs (VEGF = vascular endothelial growth factor), generally on a monthly dosage scheme. We discuss recent developments for the treatment of these diseases, including bioactive tissue-engineered materials, which may reduce frequency of dosage and propose a path forward for improving patient outcomes. Graphical abstract Development of materials for long-term intravitreal delivery for management of posterior segment diseases.
视网膜生理学可能会因年龄和代谢异常而累积氧化损伤和炎症损伤。两种涉及视网膜和脉络膜新生血管的显著疾病是增生性糖尿病视网膜病变和湿性年龄相关性黄斑变性。目前，这些疾病主要通过抗血管内皮生长因子药物（VEGF = 血管内皮生长因子）治疗，通常采用每月剂量方案。我们讨论了治疗这些疾病的最新进展，包括生物活性组织工程材料，这可能会降低剂量频率，并提出改善患者治疗效果的方法。
图摘要 用于管理后节疾病的长期玻璃体内递送的材料的发展。
